Following successful beta program, the Simoa SP-X next generation benchtop and CorPlex are launching ahead of schedule to further revolutionize cancer research, immunotherapy monitoring, and drug development
Lexington, Mass. – January 10, 2019 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the much-anticipated full launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels. The new instrument platform and highly validated CorPlex assays promise to revolutionize oncology research and drug development. The progress made since the early access program was initiated in early November 2018 with select industry leaders has validated the performance and promise of the technology, resulting in an accelerated timeline for full launch. The company is now taking orders for shipping by April 1.
For the first time, researchers are able to access over one thousand assay configurations of critical immunomodulatory biomarkers for oncology research with multiplexing up to 10-plex without sacrificing sensitivity. The broad assay menu covers more than 50 analytes and enables researchers to easily develop custom homebrew assays, further extending the range of applications to include PK/PD and immunogenicity assays as well. Simoa CorPlex assays undergo extensive validation, providing one of the most highly validated assay menus in the industry, ensuring customers can utilize the assays in the most demanding clinical and translational research applications. The next generation Simoa planar array technology utilized in CorPlex assays promotes non-invasive biomarker measurements, supporting easier and more approachable methods for determining drug efficacy and toxicity. This addresses the previously unmet needs of oncology researchers, particularly in the rapidly expanding fields of immuno-oncology and immunotherapy, including checkpoint inhibitors and CAR-T cell therapies.
“Immuno-oncology-based treatments have long shown tremendous promise for improving how we treat cancers, but researchers have lacked reliable methods to test the efficacy and toxicity of those treatments early in therapeutic intervention,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix. “The ability to monitor the interaction of the patient immune system and tumor biology by measuring multiple analytes simultaneously is critical but has not been possible with sufficient sensitivity until now. The SP-X instrument with CorPlex assays mark the latest addition to our ultra-sensitive product portfolio, supplying researchers with the tools they need to determine whether immunotherapies are having the desired effect at the earliest stages of the disease, saving resources and, ultimately, lives.”
While immunotherapies have gained traction as a promising way to treat many cancers, the inability to optimize dosing and the occurrence of immune-related adverse events have hindered progress. Critical biomarkers that would enable researchers to make informed decisions with respect to dosing and toxicities are often at such low concentrations that the reliable measurement has been problematic until now. With Simoa CorPlex assays, researchers can measure concentrations of key circulating cytokines and immunological biomarkers across all stages of disease progression including normal healthy baseline levels. This means that researchers will be able to more quickly see whether the immunotherapy or other cancer treatments are working, or potentially avoid severe side effects such as neurotoxicity and cytokine release syndrome. This means the Simoa CorPlex could have the potential to catalyze dramatic reductions in treatment costs, which can amount to several hundred thousand dollars a year.
General availability of Simoa CorPlex is made possible by the SP-X Imaging and Detection System, Quanterix’ new state-of-the-art benchtop imager that utilizes a proprietary planar array technology, offering advanced multiplexing capabilities with the same Simoa sensitivity found in the company’s HD-1 and SR-X instruments. Building on the success of Quanterix’ flagship Simoa technology, the SP-X and Simoa CorPlex are meeting the needs of oncology researchers with the goal of revolutionizing patient care.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include statements relating to the promise of the SP-X and Simoa Corplex to revolutionize oncology research and drug development, and are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.